Alpharadin (radium-223)

///Alpharadin (radium-223)

Skeletal Events and the Treatment of Men with Advanced Prostate Cancer

Many of our doctors are constantly vigilant about our developing skeletal related issues.   Having advanced prostate cancer and receiving treatment for this disease increases our odds of developing skeletal issues which affect both our quality of life and our mortality.

Drugs like denosumab (Xgeva) and zoledronic acid (Zometa) are important in delaying the onset of skeletal related event complications, however neither of these drugs improve survival nor delay mortality. They both are beneficial and have an important role in delaying the complications of bone metastases in men with metastatic castrate resistant prostate cancer (mCRPC).

The two new “super” ADT drugs that have […]

We Need Your Story To Save The CDMRP – If You Have Benefitted From Xfigo, Xtandi or Zytiga Let Me Know

Most people don’t know the many advances that the Department of Defense Congressionally Directed Medical Research Program (DOD PCRP) has brought to the PROSTATE CANCER COMMUNITY.  Did you know that the program is directly responsible for funding the initial development of three of the very new drugs we have available?

The DOD PCRP is directly responsible for the development of:

ZYTIGA

XTANDI

XOFIGO

Without the funding from the DOD PCRP we would not have these life extending treatments!

Besides these drugs the DOD PCRP has funded other investigational treatments which are either in or preparing to enter into clinical trials.  The DOD PCRP has also funded […]

Quality Control Of Xofigo – Confirming That Intravenous Radium-223 Actually Becomes Systemic and Doesn’t Leak At The Injection Site

Radium-223 dichloride (Xofigo) has been approved as an intravenous radiotherapy for men with castration-resistant prostate cancer (CRPC) who have multiple osseous (bone) metastases. Most often, it is used in men who have too many metastases to treat with spot radiation.

Xofigo works by mimicking calcium that is attracted to bones. To be successful the drug must successfully circulate through out the body to be able to find all of the metastases. A recent study evaluated the ability of the intravenous introduction of the Xofigo to properly circulate through the body.

The researchers relied on the fact that […]

NICE Reverses Its Decision and Now Recommends Radium-223 (Xofigo) For Men Who Have Had Chemotherapy

According to Prostate Cancer UK The National Institute for Health and Care Excellence (NICE) has released its second draft decision on the availability of radium-223 (Xofigo). Different from the original draft this draft recommends that radium-223 be made available on the NHS for men with advanced prostate cancer that no longer responds to hormone therapy (castrate resistant prostate cancer) that has also spread to the bones. However, they only recommend it for these men if they’ve already been treated with chemotherapy.

The Scottish Medicines Consortium (SMC), which operates independently of NICE, hasn’t yet considered radium-223 availability on the NHS in Scotland. […]